Mirion reports Q2 adjusted EPS 11c, consensus 10c

Reports Q2 revenue $222.9M, consensus $216.2M. “Our second quarter results demonstrate continued progress towards key 2025 financial targets and positively position us to capture robust market dynamics,” commented Mirion’s (MIR) Chairman and Chief Executive Officer Thomas Logan. “Nuclear power and cancer care tailwinds remain vibrant and Mirion is better positioned than ever to capitalize on these favorable market trends. We improved our strategic positioning and operating performance while successfully minimizing our tariff exposure to date.”